Journal: bioRxiv
Article Title: A Novel Drug Candidate that Selectively Targets the Critical Androgen Receptor-ELK1 Growth Axis in Advanced and Drug-Resistant Prostate Cancer
doi: 10.64898/2026.05.26.727474
Figure Lengend Snippet: Panels A-I: Viability of VCaP cells, LNCaP cells or CWR22Rv1-AR-EK cells was determined at the indicated time points of treatment with vehicle or three concentrations of the enzalutamide, KCI807 or KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values. For statistical analysis, the treatment curves were compared in each case with the corresponding vehicle control as described under Methods. Panels J-M: Viability of the AR-negative DU145 cells, MDA-MB-231 cells, HeLa cells and MDA-MB-231 cells was determined at the end of four days of treatment with vehicle and two concentrations of KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values, considering the Day 0 values to be 100 percent. Statistical analysis of the histograms, conducted as described under Methods, did not show significant effects of the compounds.
Article Snippet: 22Rv1 cells, LNCaP cells, VCaP cells, DU145 cells, A549 cells, MDA-231 cells and HeLa cells were purchased from ATCC and frozen after less than 5 passages.
Techniques: MTT Assay, Control